News & Events

The Firm is representing Arbor Pharmaceuticals, LLC in its announced acquisition of XenoPort, Inc. (NASDAQ: XNPT) for $7.03 per share in cash, or a total equity value of approximately $467 million. The transaction, which has been unanimously approved by both the Arbor Board of Directors and the XenoPort Board of Directors, is expected to close in the third quarter of 2016. Closing of the transaction is subject to certain regulatory and other customary closing conditions.

Arbor Pharmaceuticals, headquartered in Atlanta, Georgia, is a specialty pharmaceutical company currently focused on the cardiovascular, hospital and pediatric markets. The company has over 600 employees including 500 sales professionals promoting its products to physicians, hospitals and pharmacists. Arbor currently markets twenty NDA or ANDA approved products with over 35 more in development.

XenoPort, Inc. is a biopharmaceutical company focused on commercializing HORIZANT in the United States.  

The Simpson Thacher team includes Gary Horowitz and Ravi Purushotham (M&A); and James Cross (Credit).